Fundraising Fox
/Companies
Sign in

Calviri

Phoenix, US · Founded 2015 · Delaware corporation · 1 known investors

Find your way into Calviri

Sign up to see every warm intro you have to Calviri

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Calviri team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Calviri is a biotechnology company developing multi-cancer blood tests and cancer vaccines for dogs and humans, based on antigens said to be shared across tumors. Its first commercial product is StageOne Plus, a canine multi-cancer, multi-stage diagnostic test, and it is also running clinical trials of preventative and therapeutic canine cancer vaccines.

Biotech

Founders & leadership

Calviri was founded in 2015 by Stephen Albert Johnston.

SAStephen Albert Johnston
Stephen Albert Johnstonco-Founding CEOStephen Albert Johnston developed the SimpleAI system for identifying solutions to biological problems and has authored work on nucleic acid vaccines, gene expression technologies, and diagnostic methods. He currently serves as executive officer at Calviri, focusing on RNA-based vaccine development and diagnostic array technologies.
KSKathryn Sykes
Kathryn SykesVice President Research & Product Development
GP
George PosteNamed on SEC filing
NW
Neal WoodburyNamed on SEC filing
AB
Anna BarkerNamed on SEC filing

Board

JJ
Jacque J. SokolovBoard director
MM
Michael McCallisterBoard director
JL
Jeffrey Le BengerBoard director

Investors · 1

Funding

SEC filings, press & company announcements

$19.7M disclosed across 8 rounds · 2018–2024

▶$785KraisedNov 2024 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kathryn SykesDirector
  • Jeffrey Le BengerDirector
  • Michael McCallisterDirector
  • Stephen Albert JohnstonExecutive Officer, Director
  • Jacque J. SokolovDirector
Offering amount
$5M
Amount sold
$785K
Minimum investment
$25K
First sale
Oct 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$150KraisedSep 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen Albert JohnstonExecutive Officer, Director
  • Jacque J. SokolovDirector
  • Michael McCallisterDirector
  • Jeffrey Le BengerDirector
  • Kathryn SykesDirector
Offering amount
$2M
Amount sold
$150K
Minimum investment
$25K
First sale
Sep 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$650.2KraisedOct 2023 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen Albert JohnstonExecutive Officer, Director
  • Jacque J. SokolovDirector
  • Jeffrey Le BengerDirector
  • Michael ChambersDirector
  • Kathryn SykesDirector
  • Michael McCallisterDirector
Offering amount
$30M
Amount sold
$650.2K
Minimum investment
$10K
First sale
Sep 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.1MraisedMay 2023 · 32 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jacque J. SokolovDirector
  • Michael McCallisterDirector
  • Stephen Albert JohnstonExecutive Officer, Director
  • Jeff Le BengerDirector
  • Michael ChambersDirector
  • Kathryn SykesDirector
Offering amount
$11.1M
Amount sold
$11.1M
Minimum investment
$25K
First sale
Oct 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedOct 2020 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kathryn SykesDirector
  • Stephen Albert JohnstonExecutive Officer, Director
  • Michael ChambersDirector
  • Michael McCallisterDirector
  • Jacque J. SokolovDirector
Offering amount
$5M
Amount sold
$2.4M
Minimum investment
$25K
First sale
Sep 2020
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$430KraisedOct 2020 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kathryn SykesDirector
  • Stephen Albert JohnstonExecutive Officer, Director
  • Jacque J. SokolovDirector
  • Michael ChambersDirector
  • Michael McCallisterDirector
Offering amount
$5M
Amount sold
$430K
Minimum investment
$25K
First sale
Sep 2020
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.9MraisedMar 2020 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • George PosteDirector
  • Stephen Albert JohnstonExecutive Officer, Director
  • Kathryn SykesDirector
  • Neal WoodburyDirector
  • Jacque J. SokolovDirector
  • Anna BarkerDirector
Offering amount
$2.3M
Amount sold
$1.9M
Minimum investment
$25K
First sale
Dec 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 6

KaliVir ImmunotherapeuticsKaliVir develops oncolytic virus immunotherapies for cancer treatment based on its Vaccinia Enhanced Template (VET) backbone, which uses proprietary genetic modifications to a vaccinia virus optimized for intravenous systemic delivery and expression of therapeutic transgenes within tumors. The technology targets tumor replication and metastatic spread while modulating anti-tumoral immunity.
Anivive LifesciencesAnivive develops new medicines for companion animals, using software across the drug development process to accelerate the creation of treatments. It serves the animal health community, focusing on veterinary and pet health pharmaceuticals.
Kyverna TherapeuticsKyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.
Triumvira ImmunologicsTriumvira is a clinical-stage immuno-oncology company developing autologous and allogeneic T cell therapeutics for cancer treatment. The company applies T cell biology and targeted immunotherapy approaches to address oncology.
Dvm360dvm360 is a veterinary medicine news and education publisher, delivering clinical articles, video shorts, continuing education, and conference coverage for veterinarians, technicians, and practice staff. It also produces a digital edition and reports on industry developments across the veterinary profession.
Torigen PharmaceuticalsTorigen provides cancer diagnostics and personalized immunotherapy for veterinary patients, partnering with veterinary clinics to offer specialty pathology and autologous cancer vaccines made from a patient's own tumor tissue. Its approach targets tumor-specific antigens to treat cancer in pets.

Companies working in the same space as Calviri.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$299.6K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Calviri do?
Calviri is a biotechnology company developing multi-cancer blood tests and cancer vaccines for dogs and humans, based on antigens said to be shared across tumors. Its first commercial product is StageOne Plus, a canine multi-cancer, multi-stage diagnostic test, and it is also running clinical trials of preventative and therapeutic canine cancer vaccines.
Who founded Calviri?
Calviri was founded by Stephen Albert Johnston in 2015.
Who are Calviri's investors?
Calviri's investors include Golden Seeds.
How much funding has Calviri raised?
Calviri has disclosed $19.7M raised across 8 rounds.
Where is Calviri headquartered?
Calviri is headquartered in Phoenix, US.